Article

Development of a Novel Medium Throughput Flow-Cytometry Based Micro-Neutralisation Test for SARS-CoV-2 with Applications in Clinical Vaccine Trials and Antibody Screening

2023-01-18

Abstract excerpt

Quantifying neutralising capacity of circulating SARS-COV-2 antibodies is critical in evaluating protective humoral immune responses generated post-infection/post-vaccination. Here we describe a novel medium-throughput flow cytometry-based micro-neutralisation test to evaluate Neutralising Antibody (NAb) responses against live SARS-CoV-2 Wild Type and Variants of Concern (VOC) in convalescent/vaccinated population...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 03a981d9-2ffc-5cea-9f35-5794dddad9d7
DOI: 10.1101/2023.01.18.23284713

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Development of a Novel Medium Throughput Flow-Cytometry Based Micro-Neutralisation Test for SARS-CoV-2 with Applications in Clinical Vaccine Trials and Antibody ScreeningDOI 10.1101/2023.01.18.23284713Read

Sub-optimal Neutralisation of Omicron (B.1.1.529) Variant by Antibodies induced by Vaccine alone or SARS-CoV-2 Infection plus Vaccine (Hybrid Immunity) post 6-monthsSemantic proximity Read

A High-Throughput Broad Neutralizing Antibody Assay for Detecting SARS-CoV-2 Variant Immunity in PopulationSemantic proximity Read

Optimisation of a multiplexed, high throughput assay to measure neutralising antibodies against SARS-CoV-2 variantsSemantic proximity Read

Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serumSemantic proximity Read

A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2Semantic proximity Read

Improved Neutralisation of the SARS-CoV-2 Omicron Variant following a Booster Dose of Pfizer-BioNTech (BNT162b2) COVID-19 VaccineSemantic proximity Read

Biologically contained Ebola virus enables standardised neutralisation testing for preclinical and clinical immunogenicity assessmentSemantic proximity Read

Rapid, High Throughput, Automated Detection Of SARS-Cov-2 Neutralizing Antibodies Against Native-Like Vaccine And Delta Variant Spike TrimersSemantic proximity Read

Accurate evaluation of live-virus microneutralization for SARS-CoV-2 variant JN.1Semantic proximity Read

Assessment of the Biological Impact of SARS-CoV-2 Genetic Variation Using an Authentic Virus Neutralisation Assay with Convalescent Plasma, Vaccinee Sera, and Standard Reagents.Semantic proximity Read

Neutralisation hierarchy of SARS-CoV-2 Variants of Concern using standardised, quantitative neutralisation assays reveals a correlation with disease severity; towards deciphering protective antibody thresholdsSemantic proximity Read

Scalable, Micro-Neutralization Assay for Qualitative Assessment of SARS-CoV-2 (COVID-19) Virus-Neutralizing Antibodies in Human Clinical SamplesSemantic proximity Read